However, the observed differences in median values suggest a possible elevation of this parameter, similar to what has been reported in other cancers, such as prostate, breast, ovarian, and osteosarcoma, where higher RLN2 levels were associated with advanced disease and poorer prognosis [37,38,39]. Here, RLN2 is linked to osteosarcoma.